Evidence map›Paper›PMID 40826521›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Transforming Cancer Nanotechnology Data Analysis and User Experience. Part I: Current Challenges and Solutions Provided by caNanoLab.

Weina Ke, Rui He, Mark A Jensen, Marina A Dobrovolskaia

Abstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Weina KeBioinformatics and Computational Science, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Rui HeEssential Software, Inc., Potomac, Maryland, USA.
Mark A JensenBioinformatics and Computational Science, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, Maryland, USA.ORCID https://orcid.org/0000-0002-4233-9227

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Cancer nanotechnologies have the potential to revolutionize cancer diagnosis and treatment; however, their complexity poses challenges to data analysis and knowledge sharing. caNanoLab, a dedicated cancer nanotechnology data-sharing portal, has emerged as a valuable resource for researchers in this field. However, to fully utilize the wealth of data available in caNanoLab, there is a need for real-time descriptive statistical presentation and an optimized user experience. Herein, we provide an overview of cancer nanotechnologies and federally funded efforts to create data repositories, aiming to improve information flow and data sharing among researchers in the cancer nanotechnology field. We use caNanoLab as a case study to analyze the challenges in this area and highlight how caNanoLab addresses them. We also identify gaps and explore the potential of Large Language Models (LLMs) to improve user experience. A more detailed analysis of LLM and their applications to caNanoLab is provided in the second part of this review. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies.

Indexed as

NanomedicineNanotechnologyNeoplasmsData AnalysisHumansInformation DisseminationcaNanoLabcharacterizationdata miningdata repositorynanomedicine

Identifiers

PMID40826521
PMCPMC12361717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.